Background and Purpose-Postoperative hyperperfusion-related transient neurological deficits (TNDs) are frequently observed in adult patients with moyamoya disease who undergo direct bypass procedures. The present study evaluated the effect of the free radical scavenger edaravone on postoperative hyperperfusion in adult moyamoya disease. Methods-This study included 92 hemispheres in 72 adult patients who underwent direct bypass for moyamoya disease.
D
irect bypass procedures effectively improve cerebral hemodynamics immediately after surgery in patients with moyamoya disease (MMD). 1 However, they carry the risk of postoperative hyperperfusion that could lead to neurological deficits. [2] [3] [4] We reported previously that hyperperfusion-related transient neurological deficits (TNDs) occurred in 31.5% of adult patients who underwent direct bypass procedures. 3 The generation of reactive oxygen species is thought to play a role in the development of hyperperfusion-related TNDs. 5 In Japan, the free radical scavenger edaravone is widely used to improve neurological prognosis in acute cerebral infarction. 6, 7 This study aimed to evaluate the effect of edaravone on postoperative hyperperfusion in adult patients with MMD.
Methods

Patients and Surgical Procedures
This study included 92 hemispheres in 72 consecutive adult patients (mean age, 43.3 years; range, 19-71 years) who underwent combined direct and indirect revascularization for MMD at our hospital between April 2006 and September 2015. This study was approved by the Institutional Review Board of Hokkaido University Hospital. All patients provided informed consent. Surgical revascularization was considered for patients with hemodynamic compromise with or without clinical symptoms. The surgical procedure has been described previously. 8 Direct bypass procedures including superficial temporal artery-middle cerebral artery double anastomosis were performed in all hemispheres. In addition, indirect bypass procedures such as an encephalo-duro-arterio-myo-synangiosis were performed.
Perioperative Radiological Examinations and Management
Presurgical regional cerebral blood flow was quantitatively measured using 123 I N-isopropyl-p-iodoamphetamine single-photon emission computed tomography in all patients. Postoperative cerebral blood flow measurements were performed immediately after surgery, and at postsurgical days 2 and 7. Magnetic resonance imaging and magnetic resonance angiography were performed within 7 days postsurgery. Postoperative hyperperfusion was defined as a focal and intense increase in cerebral blood flow followed by its normalization in subsequent single-photon emission computed tomographic studies.
Uchino et al Edaravone for Symptomatic Hyperperfusion in MMD
From September 2012 (40 hemispheres in 36 patients), we administered edaravone (Tanabe Mitsubishi Pharma Co, Tokyo, Japan) in adult patients with MMD for revascularization surgeries, prospectively. At surgery initiation, 60 mg of edaravone was administered with 100 mL of normal saline. Edaravone (30 mg) was continued twice daily for 7 postsurgical days. Postsurgical systolic blood pressure was maintained at 100 to 140 mm Hg.
Data Analyses
Our interventional study used historical controls that included 52 hemispheres in 36 patients evaluated between April 2006 and August 2012, who were partially defined in a previous study. 3 The incidences of the following events were compared between the groups: (1) hyperperfusion-related TNDs, where the timing and the area of hyperperfusion corresponded with the observed neurological deficits and no fresh ischemic lesions were noted on magnetic resonance imaging; (2) hyperperfusion-associated intracranial hemorrhage; and (3) silent hyperperfusion that was not associated with neurological deficits or intracranial hemorrhages. Group data were compared using the χ 2 or unpaired t test, as appropriate. To determine the effect of various parameters on hyperperfusion-related TNDs, multivariate logistic regression analysis was conducted on factors achieving P<0.05 in the univariate analysis.
Results
Postoperative magnetic resonance angiography confirmed the patency of superficial temporal artery-middle cerebral artery anastomosis in all operated hemispheres. There were no postoperative drug-related adverse events in the edaravonetreated group. Repetition of single-photon emission computed tomography detected radiological hyperperfusion within 7 postsurgical days in 28 of 40 (70.0%) and 39 of 52 (75.0%) hemispheres in the edaravone and control groups, respectively. The incidence of radiological hyperperfusion was not significantly different between the groups (P=0.30), but hyperperfusion-related TNDs were significantly lower in the edaravone group compared with the control group (12.5% versus 32.7%; P=0.024; Table 1 ). TNDs included 14 cases of aphasia, 4 of dysarthria, 1 of motor weakness, 1 of facial palsy, 2 of sensory disturbance of the limbs, and 2 of seizures. Some patients showed several concomitant TNDs. There were no significant differences in the incidences of hyperperfusion-related intracranial hemorrhage or silent hyperperfusion between the groups ( Table 1) .
As shown in Table 2 , univariate analysis demonstrated that hyperperfusion-related TNDs were significantly correlated with left-sided surgery (P=0.005) and edaravone administration (P=0.024). Multivariate analysis confirmed a significant independent correlation of these 2 factors with hyperperfusion-related TNDs (P=0.009 and P=0.037, respectively). The other investigated factors were not associated with hyperperfusion-related TNDs ( Table 2) .
Discussion
Several hemodynamic factors could interact to cause postoperative hyperperfusion in MMD, including a large pressure gradient caused by autoregulatory vasodilation of the recipient arteries in response to chronic cerebral ischemia, a large superficial temporal artery size relative to the recipient middle cerebral artery, and poor distribution of bypass flow. [2] [3] [4] 9 In these situations, the excessive arterial blood supply could cause oxidative stress that would generate free radicals, which could damage the blood-brain barrier. 5, 10 This would then cause vasogenic edema and disturbance of the vascular circulation. 5 These processes, in addition to the direct toxic effect of free radicals on neurons, could disrupt the neurovascular unit, causing hyperperfusion-related TNDs. 5 We hypothesized that perioperative administration of edaravone may protect the neurovascular unit and suppress hyperperfusion-related TNDs by reducing free radical production during hyperperfusion. As expected, this study showed that edaravone administration reduced the incidence of hyperperfusion-related TNDs in MMD. In contrast, edaravone might not affect the occurrence of hyperperfusion, in which case, the above-mentioned hemodynamic factors would be involved rather than free radicals. 11, 12 Similarly, edaravone did not prevent hyperperfusion-related intracranial hemorrhages, which are caused by excessive hemodynamic alterations after revascularization, suggesting the potential involvement of preexisting blood-brain barrier vulnerability. 13 For hyperperfusion management, strict perioperative blood pressure control is essential. 14 Recently, minocycline has also been reported to prevent hyperperfusion-related TNDs; the mechanism of this has been suggested to be similar to that of edaravone. 2 The present study had some limitations. First, the study used historical controls rather than randomized placebo controls. Therefore, the possibility of confounding factors cannot be excluded. Second, the preoperative status of cerebral hemodynamics was not included in the analysis. We previously reported that a preoperative elevation in cerebral blood volume was a risk factor for postoperative hyperperfusion in patients with MMD. 3 However, the positron emission tomographic parameters, including cerebral blood volume, were not measured in the edaravone group. Therefore, the possibility of cerebral hemodynamic heterogeneity between the groups cannot be ruled out. Third, the pathophysiological processes during hyperperfusion in MMD are not understood completely. Further studies are needed to elucidate the mechanisms of edaravone action during hyperperfusion, as well as to understand the mechanisms underlying hyperperfusion occurrence in MMD.
Conclusions
The free radical scavenger edaravone reduced the incidence of postoperative hyperperfusion-related TNDs. Therefore, edaravone may be useful for reducing hyperperfusion-related complications after revascularization surgery in adult patients with MMD. To confirm these results, additional randomized control studies are needed in future.
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